HEME Home Transfusion Program

Summary

This research study is evaluating whether a new care delivery program that provides access to home blood transfusions in hospice (i.e, HEME-Hospice) compared to regular standard of care improves quality of life, mood, and end-of-life health care utilization for patients with hematologic malignancies.

Eligibility

Inclusion Criteria for Patient Participants:

* Diagnosis of a relapsed/refractory hematologic malignancy
* Age ≥ 18 years
* Receipt of primary oncologic care at DFCI (at least 2 outpatient visits in 12 months prior to enrollment)
* Has received at least one red blood cell (RBC) or platelet transfusion since blood cancer diagnosis in the clinic or hospital setting without a severe transfusion reaction
* Patient resides within catchment served by Care Dimensions Hospice
* Physician-estimated prognosis of six months or less

Inclusion Criteria for Caregivers:

* Identified informal caregiver of enrolled patient with hematologic malignancy
* Age ≥ 18 years

Exclusion Criteria for Patient Participants:

* Age \< 18 years
* Already enrolled in hospice
* Resides in nursing home or assisted living facility
* History of previous serious adverse transfusion reaction

Exclusion Criteria for Caregivers:

-Age \< 18 years

Conditions7

Locations2 sites

Browse More Trials